- Previous Close
0.2000 - Open
0.1950 - Bid 0.1900 x --
- Ask 0.2400 x --
- Day's Range
0.1920 - 0.2000 - 52 Week Range
0.1510 - 0.5900 - Volume
76,000 - Avg. Volume
128,614 - Market Cap (intraday)
76.603M - Beta (5Y Monthly) 2.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
spagonanomedical.seRecent News: SPAGO.ST
View More
Performance Overview: SPAGO.ST
Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPAGO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPAGO.ST
View MoreValuation Measures
Market Cap
69.64M
Enterprise Value
21.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.94
Price/Book (mrq)
1.39
Enterprise Value/Revenue
12.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.70%
Return on Equity (ttm)
-29.41%
Revenue (ttm)
6.28M
Net Income Avi to Common (ttm)
-33.09M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
47.7M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.6M
Research Analysis: SPAGO.ST
View MoreCompany Insights: SPAGO.ST
SPAGO.ST does not have Company Insights